Antitumor Effect of Periplocin in TRAIL-Resistant Human Hepatocellular Carcinoma Cells through Downregulation of IAPs
Figure 5
Periplocin treatments affected tumor growth in xenograft in vivo model. HCC cells were subcutaneously injected into SCID mice at 3 × 106 cells. Periplocin was IP injected into SCID mice daily two weeks after initial tumor injection (5 mg/kg on day 15 to day 29 and 20 mg/kg on day 29 to day 35). (a) Tumor size was measured every 2–4 days throughout the study (). (b) Body weight of control and treated mice were measured every 2–4 days throughout the study. (c) After the mice were sacrificed, tissue sections were prepared and stained with anti-Ki67 and anticyclin-D1 antibodies to evaluate cell proliferation. (d) Huh-7 cells were fixed, and immunofluorescent stained by Hoechst 33258 (blue staining), Ki67 (red staining), and cyclin-D1 (green staining).
